|
|
Global Functional Genomics IndustryPublished by: Scope eKnowledge Center Ltd. Published: Nov. 1, 2002 - 115 Pages Table of ContentsIntroduction
AbstractThanks to the Human Genome Project (HGP), a slew of technologies have been developed to facilitate the gene sequencing process. The genomics upheaval due to the Human Genome Project has generated remarkable opportunities for the pharmaceutical, biotechnology and health services industries. The resulting study of functional genomics facilitates the identification of genes within the genome along with the proteins they express and helps in the identification of their various functions. Technologies such as microarrays, down regulation technologies and animal models are likely to revolutionize drug discovery and the delivery of health services, thereby creating newer opportunities for the pharmaceuticals, biotechnology and healthcare industries.To operate profitably in the highly competitive pharmaceutical market, both pharma and biotech companies need to keep themselves updated with emerging technologies as well as be in a position to integrate them and discover newer certified/validated targets for commercial exploitation. This in turn is likely to hasten the evolution of new areas such as functional genomics. With current revenues at around $ 940 million, Scope forecasts the functional genomics market to become more dominant in the future and increase to around $2.2 billion by 2007. The industry is expected to grow at a rate of around 18 percent per annum until 2007. The functional genomics industry is highly fragmented but is seeing increased consolidation in the form of alliances and acquisitions with the action being primarily concentrated in the US and Europe. The industry is also highly R&D intensive and as such issues such as patents, data management and compatibility of data will continue to dominate the industry. This report by Scope critically examines the state of the global functional genomics industry as it exists today and provides insights on market segmentation, current market size, major players, end user analysis, major trends and key industry drivers. The report also provides brief profiles of some of the leading players in the market including Affymetrix, Agilent, Amersham BioSciences, Apogent Technologies, Applied Biosystems, Atugen Inc, BD Clontech, Isis, Nanogen and PerkinElmer. |
|
|||
|
About MarketResearch.com
|
||||